12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Afrezza: Completed Phase III enrollment

MannKind completed enrollment in the open-label, international Phase III Study 171 trial comparing Afrezza using the inhaler MannKind used in Phase III testing vs. Afrezza administered via the MedTone commercial inhaler or injected rapid-acting insulin in at least 471 Type I diabetics....

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >